Trump Signs Order Fast-Tracking Psychedelic Drug Review; Eases FDA Restrictions
Summary
President Trump signed an executive order to expedite FDA review and access to psychedelic drugs like ibogaine, which veteran groups advocate for PTSD treatment, with podcaster Joe Rogan joining the signing event.
How coverage differs
Left outlets highlight the risks of fast-tracking controversial drugs like ibogaine, while right outlets praise Trump's proactive move to ease restrictions for therapeutic benefits, especially for veterans.
- Left: Expediting controversial psychedelic drug review bypasses critical safety protocols Left-leaning outlets report President Trump's executive order to expedite FDA review of psychedelic drugs, specifically highlighting the inclusion of the 'controversial drug ibogaine.' This coverage emphasizes the potential risks or contentious nature surrounding the fast-tracking of such substances.
- Center: Executive order fast-tracks review of controversial psychedelic drugs Center outlets factually report President Trump's executive order to accelerate the FDA review process for psychedelic drugs, including ibogaine. They explain the order's intent to ease existing FDA restrictions and its potential impact on treatments for conditions like PTSD.
- Right: Cutting red tape to deliver psychedelic therapies for veterans Right-leaning outlets frame President Trump's executive order as a decisive action to speed the FDA's review of psychedelic drugs, aiming to ease restrictions. This coverage likely emphasizes the potential therapeutic benefits for conditions like PTSD, particularly for veterans, and Trump's proactive approach.